Literature DB >> 16524595

The natural history and long-term outcome of 57 limb sarcoidosis neuropathy cases.

T M Burns1, P J B Dyck, A J Aksamit, P J Dyck.   

Abstract

Fifty-seven patients with biopsy-proven sarcoidosis causing limb neuropathy were reviewed in order to delineate the characteristic symptoms, impairments, disability, course, outcome and response to corticosteroid treatment of limb sarcoid neuropathy. Typically the neuropathy had a definite date of symptomatic onset. Prominent were positive neuropathic sensory symptoms (P-NSS), especially pain, overshadowing weakness and sensory loss. P-NSS were the main cause of disability. Almost always the pattern was asymmetric and not length-dependent (unlike distal polyneuropathy). We inferred (from kind and distribution of symptoms, signs and electrophysiologic and other test results) that the pathologic process was focal or multifocal, involving most classes of nerve fibers and variable levels of proximal to distal levels of roots and peripheral nerves. Additional features aiding in diagnosis were: systemic symptoms such as fatigue, malaise, arthralgia, fever and weight loss; involvement of multiple tissues (i.e. skin, lymph nodes and eye); the patterns of neuropathy; MRI features; and ultimately tissue diagnosis. Axonal degeneration predominated, although an acquired demyelinating process was observed in 3 patients. For most cases, the disease had a chronic, monophasic course. MRI studies done in later years of affected neural structures were helpful in identifying leptomeningeal thickening, hilar adenopathy; and enlargement and T2 enhancement of nerve roots, plexuses, and limb nerves. Corticosteroid treatment appeared to ameliorate symptoms more than impairments. Several variables were associated with neuropathic improvement: CSF pleocytosis, short duration between symptom onset and treatment, and a higher grade of disability at first evaluation-a possible rationale for future earlier diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16524595     DOI: 10.1016/j.jns.2006.01.014

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  15 in total

1.  Utility of skin biopsy to evaluate peripheral neuropathy.

Authors:  Arthur P Hays
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

Review 2.  Peripheral neuropathy: clinical and electrophysiological considerations.

Authors:  Tae Chung; Kalpana Prasad; Thomas E Lloyd
Journal:  Neuroimaging Clin N Am       Date:  2013-05-25       Impact factor: 2.264

3.  A case of neurosarcoidosis that presented with symptoms of Guillain-Barré syndrome.

Authors:  A Oldroyd; T Dawson; J Nixon
Journal:  BMJ Case Rep       Date:  2011-04-01

4.  Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

Authors:  Lara Heij; Marieke Niesters; Maarten Swartjes; Elske Hoitsma; Marjolein Drent; Ann Dunne; Jan C Grutters; Oscar Vogels; Michael Brines; Anthony Cerami; Albert Dahan
Journal:  Mol Med       Date:  2012-11-15       Impact factor: 6.354

Review 5.  Sarcoidosis and small-fiber neuropathy.

Authors:  Jinny Tavee; Daniel Culver
Journal:  Curr Pain Headache Rep       Date:  2011-06

Review 6.  Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy.

Authors:  Roy Freeman
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

7.  Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis.

Authors:  Bastien Joubert; Catherine Chapelon-Abric; Lucie Biard; David Saadoun; Sophie Demeret; Didier Dormont; Matthieu Resche-Rigon; Patrice Cacoub
Journal:  JAMA Neurol       Date:  2017-11-01       Impact factor: 18.302

8.  Neurosarcoidosis: clinical review of a disorder with challenging inpatient presentations and diagnostic considerations.

Authors:  J Chad Hoyle; Courtney Jablonski; Herbert B Newton
Journal:  Neurohospitalist       Date:  2014-04

9.  Autoimmune neuromuscular disorders.

Authors:  Jessica Kraker; Saša A Zivković
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

10.  Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting.

Authors:  Emilio Blanco Tarrio; Rafael Gálvez Mateos; Enric Zamorano Bayarri; Vanessa López Gómez; Maria Pérez Páramo
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.